CTOs on the Move

MAP Pharmaceuticals

www.mappharma.com

 
MAP Pharmaceuticals is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mappharma.com
  • 2400 Bayshore Pkwy Suite 200
    Mountain View, CA USA 94043
  • Phone: 650.386.3100

Executives

Name Title Contact Details

Similar Companies

LifeWays

LifeWays is the Community Mental Health Agency for Jackson and Hillsdale Counties. We provide specialty mental health services to individuals with Medicaid or Healthy Michigan, living in Jackson or Hillsdale County. Once someone receives a screenin...

Open Door Health

Open Door Health Services has local healthcare clinics in Muncie & Anderson IN. Visit our site to learn about affordable health services. Contact us today!

Sertech

Sertech is a Batavia, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AbbVie

At AbbVie, we believe the world needs new approaches to addressing today`s health issues — from life-threatening illness to chronic conditions. We combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people`s lives. With 28,000+ employees and medicines in over 170 countries, AbbVie is uniting the best of pharma and the boldness of biotech, to innovate end-to-end approaches that make a real difference in people`s lives.

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.